[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mpnst\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mpnst":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,72,105,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053719","phase-2-trial-of-selumetinib-and-bromodomain-inhibitor-with-durvalumab-for-sarcomas-100053719",false,"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas","Phase 1\u002F2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors","Inclusion Criteria:\n\nInclusion Criteria AGE: ≥ 18 years of age Weight: \\>30 kg Life expectancy of at least 12 weeks\n\nPart A and B (Phase 1): Patients with histologically confirmed soft tissue or bone sarcoma of the following subtypes:\n\n* MFH\u002F undifferentiated pleomorphic sarcoma\n* Unclassified sarcoma\n* Rhabdomyosarcoma\n* Malignant peripheral nerve sheath tumor (MPNST)\n* Osteosarcoma\n* Ewing or Ewing-like sarcoma\n* Synovial sarcoma\n* Desmoplastic small round blue cell tumor (DSRCT)\n\nPatients must have progressed or demonstrated disease that is refractory to standard therapies.\n\nPatients for whom no standard of care treatments exist are eligible.\n\nPart C (Phase 2): Patients with progressive, relapsed, unresectable or metastatic NF associated MPNST.\n\nMEASURABLE DISEASE:\n\nPatients must have evaluable or measurable disease (Phase 1) and measurable disease by RECISTv1.1 (Phase 2).\n\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study excluding chronic grade 1 toxicities and alopecia.\n* No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.\n* Myelosuppressive chemotherapy: The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks (≥21 days) and 42 days if prior nitrosourea prior to study entry.\n* Immunotherapy: The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry.\n* Biologic (anti-cancer agent): The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry. Prior therapy with a MEK, Ras, or Raf inhibitor used for treatment of malignant sarcoma is not allowed. Prior therapy of MEK, Ras, or Raf inhibitor for other tumor such as plexiform neurofibroma or glioma is allowed.\n* Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study\n* Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry.\n* Stem Cell Transplantation. At least 2 months post-autologous stem cell transplant.\n* Growth Factors. The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry.\n* Karnofsky performance level ≥ 50% (See Appendix II).\n* Patients who are unable to walk because of paralysis or motor weakness, but who are able to use a wheelchair will be considered ambulatory for the purpose of calculating the performance score.\n\nHemoglobin ≥9.0 g\u002FdL (transfusion permissible)\n\n* Peripheral absolute neutrophil count (ANC) of ≥1000\u002FµL\n* Platelet count ≥100,000\u002FµL (transfusion independent (no transfusion within at least 7 days prior to enrollment))\n* Total bilirubin must be ≤ 1.5 times the upper limit of normal (ULN)\n* SGOT (AST)\u002FSGPT (ALT) must be ≤ 3.0 times ULN unless liver metastases are present, in which case it must be ≤ 5x ULN\n\nRENAL FUNCTION:\n\nSerum creatinine ≤ 1.5 times ULN or measured reatinine clearance \\>50 mL\u002Fmin or calculated creatinine clearance \\> 50 mL\u002Fmin by the Cockcroft- Gault formula (Cockgraft and Gault 1976) or by the 24 hour urine collection for determination of creatinine clearance\n\n* Normal ejection fraction (ECHO or cardiac MRI) ≥53% (or the institutional normal; if a range is given then the upper value of the range will be used)\n* QTC or QTcF ≤ 450msec\n\nFertile men and women of childbearing potential must agree to use an effective method of birth control.\n\nFemale participants of childbearing potential must be willing to practice highly effective contraception as detailed below from the time of screening until 3 months after discontinuing the study.\n\nThey must not be breastfeeding and must have negative pregnancy test prior to start of dosing.\n\nFor a female participant to be considered as of not childbearing potential, she should fulfil one of the following:\n\nPost-menopausal women, defined as either women aged more than 50 years and have amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments, or, women under 50 years who have amenorrhea for at least 12 months following cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in the postmenopausal range for the institution.\n\nor\n\n* Have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (but not tubal ligation)\n* Have medically confirmed, irreversible premature ovarian failure.\n\nHighly effective methods of contraception are:\n\n* Use of medroxyprogesterone acetate depot injection (Depo-proveraTM). (Please note: use of any other oral, injected, or implanted hormonal methods of contraception cannot be considered highly effective as it is currently unknown whether investigational agents may reduce their effectiveness)\n* Placement of a copper-banded intrauterine device (IUD) or intrauterine system (IUS)\n* Bilateral tubal ligation\n* Vasectomized partner\n\nBarrier methods include:\n\nOcclusive cap (e.g. diaphragm or cervical\u002Fvault caps) with spermicide\n\nMale participants should either be surgically sterile or willing to use an effective barrier method of contraception during the study and for 3 months following the last dose of drug therapy if sexually active with a female of childbearing potential. If not done, storage of sperm prior to receiving drug therapy will be advised to male participants with a desire to have children.\n\nMale subjects must agree to refrain from sperm donation during and until 90 days from drug therapy discontinuation.\n\nCNS DISEASE: Patients with central nervous system disease are eligible or enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression or stable disease at 4 weeks.\n\nExclusion Criteria:History of another primary malignancy except for\n\n* A malignancy treated with curative intent and with no known active disease ≥5 years prior to study entry\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n* Adequately treated carcinoma in situ without evidence of disease\n* Stable optic pathway glioma or low grade glioma not receiving active therapy\n\nHistory of leptomeningeal carcinomatosis.\n\nPatients receiving other anti-cancer agents are not eligible.\n\nPatients who cannot swallow whole pills.\n\nHistory of allogeneic organ transplantation.\n\nCurrent or prior use of immunosuppressive medications within 14 days prior to study entry. The following are exceptions to this criterion:\n\nintranasal, inhaled, topical steroids or local steroid injection (e.g., intra-articular injection)\n\nSystemic corticosteroids used at physiologic doses not to exceed 10mg\u002Fday of prednisone or its equivalent.\n\nSteroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n\nPatients should not receive immunizations with attenuated live vaccines within four weeks of study entry or during study period.\n\nAny recent major surgery within a minimum of 4 weeks prior to starting drug therapy. Placement of vascular access device, percutaneous tumor biopsy, or bone marrows are not considered major surgical procedures and no minimum time frame prior to starting study drug.\n\nPatients who have any known severe and\u002For uncontrolled medical therapy is required.\n\nconditions or other conditions that could affect their participation in the study such as:\n\n* Severely impaired lung function defined as spirometry and DLCO that is 50%of the normal predicted value corrected for hemoglobin and alveolar volume and\u002For O2 saturation that is 88% or less at rest on room air. For patients who do NOT have respiratory symptoms (e.g., dyspnea at rest, known requirement for supplemental oxygen), pulmonary function test is not required.\n* Cardiac conditions as follows:\n\n  * Uncontrolled hypertension (blood pressure ≥150\u002F95 mmHg despite medical therapy.\n  * Acute coronary syndrome within 6 months prior to starting drug therapy\n  * Uncontrolled angina despite medical therapy (Canadian Cardiovascular Society grade II-IV despite medical therapy\n  * Symptomatic heart failure NYHA Class II-IV prior or current cardiomyopathy or severe valvular disease\n  * Prior or current cardiomyopathy including but not limited to the following: Known hypertrophic cardiomyopathy; Known arrhythmogenic right ventricular cardiomyopathy; or Previous moderate or severe impairment of left ventricular systolic function (LVEF \\\u003C45% on echocardiography or equivalent of MUGA) even if full recovery has occurred\n  * Atrial fibrillation with a ventricular rate of \\>100 beats per minute on ECG at rest\n* Uncontrolled infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Active primary immunodeficiency\n* Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome, or renal tubular acidosis.\n* Current gastrointestinal conditions such as refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of small bowel, symptomatic inflammatory bowel disease, or ulcerative colitis, or partial or complete bowel obstruction.\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (colitis, Crohn's), celiac disease, systemic lupus erythematosus, Wegener syndrome, myasthenia gravis, Graves' disease, rheumatoid arthritis, uveitis.\n\nThe following exceptions are:\n\n* Patients with vitiligo or alopecia\n* Patients with hypothyroidism (e.g., following Hashimoto's syndrome) stable on hormone replacement\n* Psoriasis that does not require systemic therapy\n* Patients with celiac disease that is controlled by diet alone\n\n  • Ophthalmological conditions as follows:\n* Current or past history of retinal vein occlusion\n* Known intraocular pressure (IOP)\\>21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma.\n* Subjects with ophthalmological findings secondary to long standing optic pathway glioma (such as visual loss, optic nerve pallor, or strabismus) or long standing orbito-temporal PN (such as vision loss, strabismus) will not be considered a significant abnormality for purposes of this study.\n\nAny Supplementation with vitamin E.\n\nHypersensitivity to investigational products, or drugs with similar chemical structures to investigational products.\n\nPatients unwilling or unable to comply with the protocol.\n\nWhile not an exclusion criterion, unless clinically indicated, patients should avoid taking other additional non-study medications that may interfere with the study medications. In particular, participants should avoid medications that are known to either induce or inhibit the hepatic activity of CYP1A2, CYP2C19, and CYP3A4.","ALL","18 Years","99 Years",{"count":20,"type":21},41,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A multi-institutional open-label phase 1\u002F2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory\u002Funresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory\u002Frelapsed sarcomas. The phase 2 portion will be for patients with refractory\u002Funresectable NF1-associated MPNST.",[27,28,29],"MPNST","NF1","Sarcoma",[27,31,28,32],"Neurofibromatosis 1","sarcoma","NOT_YET_RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":21},"2026-11-15",{"date":41,"type":21},"2032-11-15",{"name":43,"class":44},"University of Alabama at Birmingham","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100635156","phase-1-safety-and-efficacy-of-bms-986504-in-unresectable-malignant-peripheral-nerve-sheath-tumor-100635156","NCT07549022","Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor","A Phase II Trial to Assess the Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor Patients With Homozygous MTAP Deletion","Inclusion Criteria:\n\n* Male or female participants ≥ 12 years of age at the time of screening.\n* Ability to understand and willingness to sign documentation of informed consent if ≥ 18 years of age or documentation of assent if 12-17 years of age.\n* Pathohistological verification of MPNST.\n\n  * Measurable disease (size of primary tumor and metastatic lesions can be trended by CT or MRI scans).\n  * Unresectable (locally advanced or metastatic) disease.\n* Confirmation of homozygous MTAP deletion by next generation sequencing\n* Recovery from the adverse effects of prior therapy at the time of enrollment to baseline or ≤ Grade 1 (excluding alopecia, peripheral neuropathy, and parameters superseded by other eligibility criteria \\[eg, hematology parameters\\]). Note: Participants with prior endocrine adverse effects are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.\n* Recovery from the acute toxic effects (≤ grade 1 as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0) of all prior chemotherapy prior to the entering study (exceptions: alopecia, anorexia, mass pain).\n* Normal marrow function and recovery of blood cell counts from any myelosuppressive chemotherapy prior to entering study:\n\n  * Peripheral absolute neutrophil count (ANC) ≥ 1500\u002FmcL (microliter).\n  * Hemoglobin ≥ 9 g\u002FdL (packed red blood cell transfusion is not allowed up to 14 days prior to starting BMS-986504 treatment to meet eligibility).\n  * Platelet count ≥ 100,000\u002FmcL (microliter) (platelet transfusion is not allowed up to 14 days prior to starting BMS-986504 treatment to meet eligibility).\n  * Adequate organ function, including:\n\n    * Liver function:\n\n      * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) for age, or ≤ 3 x ULN if associated with liver metastatic disease or Gilbert's disease).\n      * ALT (alanine transaminase) and AST (aspartate aminotransferase) \\\u003C 3 x ULN for age, or \\\u003C 5 x ULN if associated with liver metastatic disease.\n      * Serum albumin ≥ 2.0 g\u002FdL.\n      * PT (prothrombin time) and\u002For INR (International Normalized Ratio) ≤ 1.5 x ULN, or within therapeutic range if receiving anticoagulant therapy.\n    * Renal function:\n\n      * Creatinine \\\u003C 1.5 times institutional ULN for age.\n* Performance status at time of screening:\n\n  * ECOG (Eastern Cooperative Oncology Group) performance status 0-1 for participants ≥ 18 years old.\n  * Lansky performance status (ages 12-15) or Karnofsky performance status (ages 16-17) ≥ 50.\n* Individuals of childbearing potential (IOCBP) must practice effective contraception during the trial.\n\nExclusion Criteria:\n\n* Participants who have been treated previously with a PRMT5 inhibitor.\n* Participants who are unable to swallow tablets.\n* History of gastrointestinal disease, inflammatory bowel disease, major gastric surgery or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.\n* Participants with active drug use.\n* Any botanical preparation (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study received within 4 weeks prior to randomization. The concurrent use of any botanical preparation is not permitted while on study.\n* Ongoing need for a medication known as a strong inhibitor or strong inducer of CYP3A4 and\u002For P-gp or a PPI (proton pump inhibitor) that cannot be switched to an alternative treatment prior to randomization.","12 Years",{"count":55,"type":21},17,[57,24],"PHASE1","People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available medicines for people with MPNST. Methylthioadenosine Phosphorylase (MTAP) loss is a gene mutation that some people have. MTAP loss seems to increase the chance that BMS-986504 can kill MPNST cancer cells. People who are missing MTAP from their tumor may be able to enroll in this study. Treating MPNST based on MTAP loss is considered experimental and is not approved by the US Food and Drug Administration (FDA) for determining whether BMS-98650 will be active against cancer. The purpose of this study is to evaluate the safety and effectiveness of BMS-986504 in participants with MPNST.",[60,27],"Malignant Peripheral Nerve Sheath Tumors",[62],"BMS-986504","2026-06-14",{"date":65,"type":37},"2026-06-16",{"date":67,"type":21},"2026-08",{"date":69,"type":21},"2028-07",{"name":71,"class":44},"Ankit Mangla, MD",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100514950","phase-2-a-study-of-selinexor-in-people-with-wilms-tumors-and-other-solid-tumors-100514950","NCT05985161","A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors","A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors","Inclusion Criteria:\n\n* Age:\n\n  1. Age ≥ 6 at the time of informed consent\n  2. Age ≥ 2 years to \\\u003C 6 years at time of informed consent (Refer to Section 4.3): If PK cohort 1 is open, patients in this age range may enroll onto this cohort. If PK cohort 1 has been completed and deemed sufficient to proceed, then such patients may enroll onto the phase 2.\n  3. Age ≥ 12 months to \\\u003C 2 years at time of informed consent (Refer to Section 4.3):\n\nIf PK cohort 2 is open, patients in this age range may enroll onto this cohort. If PK cohort 2 has been completed and deemed sufficient to proceed, then such patients may enroll onto the phase 2.\n\n* Consent: All patients and\u002For their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.\n* Performance: Karnofsky ≥ 60% for patients \\> 16 years of age and Lansky ≥ 60 for patients ≤ 16 years of age.\n* Diagnosis: Patients must enroll into one of the following cohorts:\n\n  1. Cohort A: Any type of Wilms tumor or nephroblastoma is eligible for this study provided they meet at least one of these criteria: (1) in their second or greater relapse, (2) refractory or in their first relapse with high risk histology (i.e., any anaplastic or blastemal-type after neoadjuvant chemotherapy), or (3) refractory or in first relapse without high risk histology but after having received chemotherapies other than the initial 4 agents used as current standard of care in the up-front setting for non-high risk cases - specifically vincristine, dactinomycin, doxorubicin, and irinotecan (i.e., any patient who relapses following an initial regimen more intense than EE4A, DD4A, VAD, AVD, or VIVA; for example, those including cyclophosphamide\u002Fetoposide - such as Regimen I, M, or MVI - or those additionally including carboplatin - such as Regimens UH-1, UH-2, or UH-3).\n  2. Cohort B: Any Rhabdoid tumor is eligible for this cohort. This includes, but is not limited to, related subtypes of rhabdoid tumors such as atypical teratoid rhabdoid tumors (ATRT), malignant rhabdoid tumors of the kidney (MRTK), malignant rhabdoid tumors of the soft tissue and liver, small cell undifferentiated hepatoblastomas (SCUH), and small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT). Patients must have failed to respond to at least 1 line of systemic therapy prior to enrollment.\n  3. Cohort C: Patients with progressive, relapsed, unresectable or metastatic MPNST, are eligible for this cohort. Patients must have failed to respond to at least 1 line of systemic therapy prior to enrollment.\n  4. Cohort D: Patients must not qualify for Cohorts A, B, or C but have a solid tumor (no hematologic malignancies including lymphoma) for which there is specific evidence that this particular patient's tumor may benefit from selinexor.\n\nPatients must have failed to respond to at least 1 line of systemic therapy prior to enrollment. Examples of evidence are listed below. All patients in this cohort require approval of study principal investigator and must provide documentation of specific supporting evidence. i. Tumor XPO1 Dependency: Defined as either Darwin OncoTarget demonstrating XPO1 as aberrantly activated or Darwin OncoTreat demonstrating context-specific tumor checkpoint inversion with Selinexor, both of which must be significant at a -log10 (Bonferroni corrected p-value) of 5 or greater. ii. Tumor XPO1 Activation: Defined as the detection of a gain of function mutation in XPO1, specifically E571K. Additionally, detection of elevated transcriptomic or proteomic expression of XPO1 in the tumor via RNAseq or IHC, respectively, would be considered sufficient for treatment.\n\niii. Preclinical Tumor Testing: Defined as testing of Selinexor on patient derived cell line, organoid, or xenograft models of the patient's tumor (or other related tumors) performed in a laboratory context and for which, in the investigator's opinion, demonstrates promising activity. Testing may include commercial testing as well as academic laboratory testing.\n\n* Cohort E: Patients must have a solid tumor with an activating genomic alteration (e.g. fusion or internal tandem duplication) involving BCOR. Specific examples of qualifying alterations including BCOR-ITD, BCOR-CCNB3, BCOR-MAML3 and ZC3H7B-BCOR; Other potentially qualifying BCOR alterations require approval of study principal investigator; note that loss of function alterations of BCOR would not qualify.\n* Disease Status: Patients on the phase II portion of the study must have measurable disease whereas patients on the PK cohorts can have either evaluable or measurable disease as measured by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (Version 1.1).\n\n  a. Primary Brain Tumors: Patients with primary brain tumors are eligible and must also have measurable disease for the phase II (as well as evaluable or measurable for the PK cohorts), but this can be defined as at least equal or greater than twice the slice thickness in two perpendicular diameters on MRI OR diffuse leptomeningeal disease OR clear MRI evidence of disease that may not be measurable in two perpendicular diameters OR positive CSF cytology alone.\n* Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and meet minimum washout durations (shown below) from prior therapy.\n\n  1. Anti-cancer agents not known to be myelosuppressive: ≥ 7 days\n  2. Anti-cancer and cytotoxic agents known to be myelosuppressive: ≥ 21 days\n  3. Immunotherapies (including antibodies, interleukins, interferons, etc.): ≥ 21 days\n  4. Adoptive cellular therapies (including modified T cells, vaccines, etc.): ≥ 42 days\n  5. Autologous stem cell infusion (boost, no conditioning): ≥ 21 days\n  6. Autologous stem cell transplantation (with conditioning): ≥ 42 days\n  7. Allogeneic bone marrow transplantation: ≥ 84 days\n  8. Focal external beam radiation (e.g., limited sites of disease): ≥ 14 days\n  9. Substantial external beam radiation (e.g. whole lung or abdomen): ≥ 42 days\n  10. Radiopharmaceutical therapy (e.g., radiolabeled antibody or MIBG): ≥ 42 days\n* Hepatic Function: Adequate function (within 14 days prior to C1D1), defined as:\n\n  1. Total bilirubin \\\u003C 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome, who must have a total bilirubin of \\\u003C3 × ULN)\n  2. Alanine aminotransferase (ALT) \\\u003C 3 × ULN\n  3. Serum albumin ≥ 2 g\u002FdL\n* Renal Function: Adequate function (within 14 days prior to C1D1) defined as a GFR\n\n  ≥ 50 ml\u002Fmin\u002F1.73 m2 determined via any of these methods:\n  1. Nuclear radioisotope\n  2. 24 hr urine creatinine clearance\n  3. Serum cystatin c\n  4. Serum creatinine using the Schwartz formula for estimating creatinine clearance (Schwartz et al. J Peds, 106:522, 1985)\n* Hematologic Function: Adequate function (within 14 days prior to C1D1), defined as:\n\n  1. Absolute neutrophil count (ANC) ≥ 1000\u002Fmm3\n  2. Platelet count ≥ 100,000\u002Fmm3\n  3. Note: patients may not receive platelet transfusions nor hematopoietic growth factor support, including granulocyte-colony stimulating factor (e.g. filgrastim) and platelet stimulators (e.g. romiplostim) for at least 7 days prior to demonstrating adequate hematologic function.\n\nExclusion Criteria:\n\n* Prior Therapy: Has received selinexor or another XPO1 inhibitor previously.\n* Infection: Patients who have an uncontrolled infection are not eligible. Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable\n* Transplants: Patients who have received allogeneic bone marrow transplant are potentially eligible unless they are being actively treated for GvHD. Patients who have had a prior solid organ transplantation are not eligible.\n* Compliance: Patients who as a result of serious medical, psychiatric, and\u002For social situation(s), in the opinion of the investigator, may not be able to comply with supportive care, safety monitoring, or any other key requirements of the study protocols are not eligible.\n* Pregnancy and Breast-feeding: Pregnant or breast-feeding women will not be entered on this study because there is yet no available information regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal.\n* Contraception: Males or females of reproductive potential may not participate unless they have agreed to use two effective methods of birth control, including a medically accepted barrier or contraceptive method (e.g., male or female condom) for the duration of the study. Abstinence is an acceptable method of birth control.","12 Months",{"count":81,"type":21},45,[24],"The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed\u002Frefractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.",[85,86,60,27,87,88,89],"Wilms Tumor","Rhabdoid Tumor","Nephroblastoma","XPO1 Gene Mutation","Solid Tumor",[85,86,60,27,87,91,92,93,94,89],"XPO1","Selinexor","Memorial Sloan Kettering Cancer Center","22-393","RECRUITING","2026-05-04",{"date":98,"type":37},"2026-05-06",{"date":100,"type":37},"2023-08-01",{"date":102,"type":21},"2029-08-01",{"name":93,"class":44},16,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100615859","dod-award-nf230020-identification-of-metabolic-markers-and-statistical-prediction-of-mpnst-for-rapid-diagnosis-and-assessment-of-surgical-margins-100615859","NCT07298083","DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins","Inclusion Criteria:\n\n1. This study will enroll approximately 60 participants diagnosed with either MPNST or neurofibroma who are undergoing surgical resection of an MPNST or neurofibroma as part of their standard of care.\n2. Age ≥ 1 years. Individuals younger than 18 years old will be included. For patients of age \\\u003C 18 years, both parents' signatures will be requested.\n3. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.\n4. Recurrent or primary disease.\n5. Patients who are \\> 18 years should have the ability to understand and the willingness to sign a written informed consent document.\n6. English and non-English speaking patients.\n\nExclusion Criteria:\n\n1. Adult patients with cognitive impairment requiring a legally authorized representative for consent.\n2. Patients under age 1 and neonates.\n3. Patients who are pregnant and undergoing surgery for MPNST are not eligible.","1 Year",{"count":113,"type":21},60,"OBSERVATIONAL","The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.",[117,27],"Neurofibromas","2026-04-08",{"date":120,"type":37},"2026-04-09",{"date":122,"type":37},"2026-04-02",{"date":124,"type":21},"2032-04-20",{"name":126,"class":44},"M.D. Anderson Cancer Center",{"id":128,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":25,"conditions":131,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100458708",{"count":20,"type":21},[24],[27,28,29],[27,31,28,32],"2026-02-06",{"date":135,"type":37},"2026-02-11",{"date":137,"type":21},"2026-05-15",{"date":139,"type":21},"2032-05-15",{"name":43,"class":44}]